Hopp til innhold

Get alerts of updates about «Ofatumumab for the treatment of relapsing remitting multiple sclerosis»

How often would you like to receive alerts from fhi.no? (This affects all your alerts)
Do you also want alerts about:

The email address you register will only be used to send you these alerts. You can cancel your alerts and delete your email address at any time by following the link in the alerts you receive.
Read more about the privacy policy for fhi.no

You have subscribed to alerts about:

  • Ofatumumab for the treatment of relapsing remitting multiple sclerosis

Health technology assessment

Ofatumumab for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment– health economic evaluation

Published

The Norwegian Institute of Public Health (NIPH) have conducted a rapid health technology assessment (HTA) of ofatumumab to treat of adults with relapsing remitting multiple sclerosis (RRMS) on behalf of the Commissioning Forum.

Forside Ofatumumab.jpg

The Norwegian Institute of Public Health (NIPH) have conducted a rapid health technology assessment (HTA) of ofatumumab to treat of adults with relapsing remitting multiple sclerosis (RRMS) on behalf of the Commissioning Forum.


Downloadable as PDF. In Norwegian. English key messages.

About this publication

  • Year: 2021
  • By: Norwegian Institute of Public Health
  • Authors Hamidi V.
  • ISBN (digital): 978-82-8406-186-3

Key message

The Norwegian Institute of Public Health (NIPH) have conducted a rapid health technology assessment (HTA) of ofatumumab to treat of adults with relapsing remitting multiple sclerosis (RRMS) on behalf of the Commissioning Forum. The evaluation was performed based on the decision model in the full HTA, previously published of NIPH, of disease modifying treatments for RRMS. The model was further updated based on the data for ofatumumab.

Ofatumumab is a fully human anti-CD20 monoclonal antibody and is administered as a subcutaneous injection. The results of our analyses showed that:

  • Rituximab is the most cost-effective treatment among anti-CD20 drugs, based on current tender prices.
  • Ocrelizumab (maximum price) is both more expensive and more effective than rituximab and cladribine (current tender prices).
  • Ocrelizumab costs NOK xxxxxxxx per quality-adjusted life year (QALY) gained compared with rituximab and cladribine with a packing dose of NOK xxxxxxxx (xxxx reduction in drug costs) and NOK xxxxxxxx (xxxx reduction in drug costs), respectively.
  • Ofatumumab is not yet markedet in Norway. Given the same health benefit and average annual drug cost (maximum price) as ocrelizumab, ofatumumab is both more expensive and more effective compared with rituximab and cladribine.
  • Given the same health benefit and annual drug cost (maximum price) as ocrelizumab, ofatumumab costs NOK xxxxxxxx per QALY compared with rituximab and cladribine with a price reduction of xxxx and xxxx, respectively.
  • A price offer of NOK xxxxxxxx (incl. VAT) per 20 mg ofatumumab gives an additional cost of NOK xxxxxxxx per QALY compared with rituximab.
  • A price offer of NOK xxxxxxxx (incl. VAT) per 20 mg ofatumumab provides more health benefits and is less expensive than cladribine.

Relapsing-remitting multiple sclerosis is a very severe disease that can cause serious disability and a loss of healthy life-years.

Due to confidentiality clauses, numbers are hidden (xxxxx).